Following the Kenvue separation, Johnson & Johnson operates a focused two-segment business model: Innovative Medicine (pharmaceuticals) and MedTech (medical devices and surgical products). This two-segment architecture represents a deliberate concentration of capital, talent, and strategic focus on the healthcare businesses with the highest margins, strongest IP protection, and most significant growth opportunities over the next decade. The Innovative Medicine segment — operating primarily through Janssen Pharmaceutica — is J&J's largest and highest-margin business, generating approximately $55 billion in annual revenue as of 2023. The pharmaceutical model is built on three interlocking economics: the patent-protected monopoly period during which a drug generates extraordinary returns (margins of 50-70% on blockbuster drugs are common), the transition period as biosimilar or generic competition erodes revenue, and the pipeline investment that continuously replenishes the portfolio with new patent-protected compounds. J&J's pharmaceutical strategy concentrates on six therapeutic areas: oncology, immunology, neuroscience, pulmonary hypertension, cardiovascular and metabolic diseases, and infectious diseases and vaccines — areas where the company believes it has differentiated scientific capabilities and where unmet medical need creates pricing power for genuinely innovative treatments. The immunology franchise is J&J's most commercially proven therapeutic platform. Remicade (infliximab) generated over $100 billion in cumulative global sales before biosimilar erosion, validating TNF-alpha inhibition as a therapeutic mechanism and establishing J&J's clinical and commercial capabilities in autoimmune disease. Stelara (ustekinumab), targeting IL-12 and IL-23 pathways, has generated over $10 billion annually at peak and remains significant despite biosimilar exposure beginning in 2023-2024. Tremfya (guselkumab), targeting IL-23 specifically, represents the next generation of selectivity in the immunology therapeutic progression and has been growing rapidly as physicians shift toward more targeted biologics. The oncology franchise has been the most transformative growth driver of the past decade. Darzalex (daratumumab) — approved initially for multiple myeloma — has expanded into multiple earlier lines of therapy and combination regimens that have made it one of the fastest-growing oncology drugs in history, with annual sales exceeding $9 billion. Erleada (apalutamide) for prostate cancer and Carvykti (ciltacabtagene autoleucel), a CAR-T cell therapy developed through a partnership with Legend Biotech, represent the breadth of J&J's oncology commitment — from small molecules to next-generation cellular therapies. The MedTech segment generates approximately $30 billion annually across three primary categories: Electrophysiology (Biosense Webster cardiac mapping and ablation systems), Orthopaedics (DePuy Synthes joint reconstruction and trauma fixation), and Surgery (Ethicon wound closure, advanced energy surgical devices, and robotics through the Ottava surgical platform under development). MedTech's business model differs structurally from pharmaceuticals: revenue is more recurring (implants require revision surgeries that generate device revenue), less subject to patent cliff risk (device improvements are iterative rather than discrete), and more dependent on surgeon relationships and hospital contracting than on physician prescription decisions. The surgical robotics investment through Ottava represents J&J's largest MedTech bet. The soft tissue robotic surgery market, where Intuitive Surgical's da Vinci platform has established near-monopoly market share, is projected to grow rapidly as robotics penetrates a broader range of surgical procedures beyond the laparoscopic gynecology and urology procedures where da Vinci dominates. J&J's Ottava platform, designed for open surgery and wound closure applications distinct from da Vinci's laparoscopic focus, represents a deliberate category differentiation strategy rather than a direct frontal assault on Intuitive's installed base. Revenue model diversity within pharmaceuticals — spanning both large molecules (biologics like Darzalex and Stelara) and small molecules (Erleada, Spravato), both immunology and oncology, both US and global markets — provides resilience against single-product revenue concentration that has historically been a vulnerability for more focused pharmaceutical companies. When Remicade began its biosimilar erosion, Stelara, Darzalex, and Tremfya had grown to levels that more than offset the loss — demonstrating the portfolio management discipline that J&J's scale enables.